Alzheimer's disease trials.
599 Alzheimer's disease trials, curated for APOE4 carriers — 347 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Stratified by APOE4 genotype specificallyNCT01211782AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
This trial tests AC-1204, an oral ketogenic compound made from caprylic triglyceride, in people with mild to moderate Alzheimer's disease. The idea is that…
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- APOE4 response explicitly analyzedNCT02292238Benfotiamine in Alzheimer's Disease: A Pilot Study
This trial is testing benfotiamine, a fat-soluble form of vitamin B1, in people with early memory problems or mild Alzheimer's. The idea is that boosting…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Built exclusively for APOE4 homozygotesNCT03634007Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
This Phase 1 trial is testing LX1001, a gene therapy delivered into the spinal fluid, in people who carry two copies of APOE4 and already have…
- Observational only, China-based populationNCT03653156China Cognition and Aging Study
This is a large observational study based in China, not a drug or treatment trial. Researchers are building a national database by following thousands of…
- Directly tests APOE4 carrier awarenessNCT03794141Genetic Information as a Life Style Change Motivator
This trial tests whether telling people they carry the APOE4 gene motivates them to make healthier lifestyle changes. Researchers also look at how learning…
- APOE4 genotype central to studyNCT03876314Physical Activity, Alzheimer's Disease and Cognition Relative to APOE Genotype
This trial is testing whether a structured physical activity program improves cognitive performance in middle-aged adults (40-65) who have a family history of…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- Directly recruits APOE4 carriers onlyNCT03978052Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Intervention
This trial is testing whether a green tea compound called EGCG, combined with a personalized lifestyle program covering diet, exercise, and cognitive training,…
- Directly recruits APOE4 carriersNCT04009629Dementia Risk and Dynamic Response to Exercise
This trial is testing how a single session of moderate aerobic exercise changes brain blood flow and blood biomarkers in older adults who carry the APOE4 gene.…
- Directly recruits APOE4 carriersNCT04430517Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia
This early-phase trial is testing nicotinamide riboside, a form of vitamin B3, in people who already have mild cognitive impairment or mild Alzheimer's…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- APOE4 carriers explicitly includedNCT04575337Study on Biomarkers for Early Diagnosis of Alzheimer's Disease
This is an observational study based in China that is tracking elderly people over five years to identify early biological markers of Alzheimer's disease.…
- Exclusively recruits APOE4 carriersNCT04693520Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
This trial is testing ALZ-801, a daily oral pill, in people who already carry one or two copies of the APOE4 gene and have early Alzheimer's disease.…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- Exclusively recruits APOE4 carriersNCT05161715Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
This trial is testing obicetrapib — a cholesterol-modifying drug — in people with early Alzheimer's disease. Researchers want to see how the drug moves through…
- Requires at least one APOE4 alleleNCT05245903Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
This trial is testing whether a supplement called nicotinamide riboside (a form of vitamin B3) produces measurable changes in brain energy metabolism in people…
- Directly recruits APOE4 carriersNCT05599425Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease
This trial tests two versions of a healthy-living education program aimed at helping middle-aged adults make lasting lifestyle changes — better diet, more…
- Directly recruits APOE4 carriersNCT05880849Choline Effects - Pre-symptomatic AD
This Phase 1 trial is testing whether choline — a common dietary supplement — is safe and tolerable in people who carry the APOE4 gene and show no symptoms of…
- Actively recruits APOE4 carriersNCT05965414Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers
This trial is testing CS6253, an injected drug, in healthy volunteers to see if it is safe and how the body processes it. It is an Early Phase 1 trial, meaning…
- Explicitly welcomes APOE4 carriersNCT06043700A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
This is a screening study, not a treatment trial. Researchers are using blood tests to find people who may have high levels of amyloid protein in the brain — a…
- Genetic study, APOE4 is the focusNCT06275243Polymorphism of ApoE in Alzheimer's Disease: Genetic Study in Castile and Leon (Spain)
This study is collecting cheek swabs from people in the Castile and Leon region of Spain to map how common the APOE4 gene variant is among people with and…
- APOE4 carriers central to studyNCT06335836The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
This trial is studying how social isolation and social interaction affect the brain and the risk of progressing from subjective cognitive decline to more…
- APOE4 homozygotes explicitly excludedNCT06474013A Clinical Trial to Evaluate the Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease
This trial is testing whether repeatedly opening the blood-brain barrier using a focused ultrasound device called ExAblate 4000 is safe and shows early signs…
- Not relevant to APOE4 carriersNCT06911944Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
This trial is testing whether donanemab, an anti-amyloid antibody already approved for early Alzheimer's, can safely reduce amyloid buildup in the brains of…
- Actively recruits APOE4 carriersNCT07007208Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk
This trial is studying a brain region called the locus coeruleus, which may show early signs of tau protein buildup before other areas affected in Alzheimer's.…
- Genotype-stratified, carriers likely eligibleNCT07027072Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
This trial is testing KDS2010, an experimental oral drug taken once daily, in people who have early Alzheimer's-related memory problems — either mild cognitive…
- APOE4-aware design, not carrier-specificNCT07208344Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease
This trial is testing whether infusing stem-like cells from donated umbilical cord blood — on top of a standard Alzheimer's drug — is safe and shows early…
- Carriers specifically sought, non-drug deviceNCT07222605Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
This pilot study tests a wearable head device called MemorEM in people with neurological diseases including Alzheimer's, Parkinson's, and frontotemporal…
- Exclusively enrolls APOE4 carriersNCT07399171Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers
This Phase 2 trial is testing an experimental drug called HT-4253 in APOE4 carriers who already show early amyloid buildup in their blood but have no dementia…
- APOE4 4/4 carriers excludedNCT07456462Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance
This study is testing whether advanced MRI scans and blood tests can predict how well lecanemab or donanemab are working in people with early Alzheimer's…
- Exclusively recruits APOE4 carriersNCT07516119Predicting Pre-dementia
This observational study is testing whether a multimodal prediction model — combining genetic risk scores, blood biomarkers, health record data, and wearable…
- Exclusively recruits APOE4 carriersNCT07646054Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers
This trial is testing whether a year-long digital lifestyle coaching program can improve blood-based markers linked to Alzheimer's risk. Twelve hundred…
- General AD trial, no APOE4 focusNCT00265148Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
This Phase 2 trial tested rosiglitazone, a drug originally developed for type 2 diabetes, against a placebo in people with mild to moderate Alzheimer's…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- APOE4 stratified, suggests less benefitNCT00428090Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…
- Closed trial, APOE4 stratifiedNCT00550420Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
This Phase 3 trial tested rosiglitazone XR, a diabetes drug, in people with mild-to-moderate Alzheimer's disease. It was an open-label extension study, meaning…
- Open to carriers, not 4-specificNCT00710684A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
This trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Observational study, no genotype requirementNCT02485730Early Identification of Markers in Alzheimer's Families / ALFA
The ALFA study is a long-term observational study — no drug or treatment is being tested. It follows adult children of Alzheimer's patients, tracking…
- Imaging study, genotype not consideredNCT02649985PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
This Phase 1 study uses specialized PET brain scans to look for microglial activation — a sign of brain inflammation — in people with multiple sclerosis and…
- Closed cohort, APOE4 not specifiedNCT02685969Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants
This study uses two types of PET brain scans to measure amyloid protein buildup and glucose metabolism in cognitively healthy adults who are mostly children of…
- Observational only, genotype not relevantNCT02811653Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
This trial is studying the relationship between movement slowness and brain changes visible on MRI in people with Alzheimer's disease and related conditions.…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Non-drug trial, genotype not consideredNCT02959502Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression
This trial is testing a home-based combination of cognitive rehabilitation (structured mental exercises) and transcranial direct current stimulation (tDCS, a…
- Discontinued trial, not APOE4-specificNCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
- Open to carriers, not 4-specificNCT03082755Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
This Phase 4 trial is testing whether gabapentin enacarbil (Horizant), a drug already approved for restless legs syndrome, can reduce nighttime agitation in…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.